Mouse and Rat Sperm Abnormality Oral Toxicity Test: Principles, Protocol, and Regulatory Application

The mouse and rat sperm abnormality oral toxicity test is a well-established in vivo genotoxicity screening assay that determines whether a test substance can induce morphological defects in sperm after repeated oral administration. Performed in accordance with standards such as GB 15193.7 and supporting the evaluation framework of ISO 10993-3, this study is a core requirement for regulatory submissions covering foods, health products, chemicals, pesticides, cosmetics, and medical devices. This article explains the scientific principles, protocol design, evaluation criteria, and practical considerations for sponsors planning studies in accredited third-party laboratories.

Technical Overview

The sperm abnormality (sperm malformation) assay in mice and rats is an in vivo mutagenicity and reproductive-toxicity screening test that detects heritable genetic damage induced in male germ cells. Spermatogenesis is a continuous, multi-stage process in which spermatogonia divide and differentiate into mature sperm over a complete spermatogenic cycle of approximately 35 days in mice. Because differentiating germ cells are highly sensitive to chemical insult, mutagenic or cytotoxic substances administered during this window can produce sperm with abnormal head or tail morphology, including amorphous heads, banana-shaped heads, hookless heads, folded heads, double heads, and double tails.

In the oral toxicity version of this test, the substance is administered by gavage (intragastric intubation) on consecutive days, reflecting the most common route of human exposure for foods, pharmaceuticals, and many chemicals. Following an appropriate post-exposure interval that covers one full spermatogenic cycle, sperm are collected from the cauda epididymis, stained, and scored microscopically. A statistically significant, dose-related increase in the sperm abnormality rate indicates that the test substance may damage germ-cell genetic material or interfere with spermatogenic differentiation.

The test is typically conducted under national food safety standard GB 15193.7 (procedure for the mouse sperm abnormality test within the toxicological assessment of food) and is frequently integrated into genotoxicity batteries alongside the bacterial reverse mutation test and the mammalian erythrocyte micronucleus test. For medical devices, the study supports genotoxicity and reproductive-toxicity evaluation within the ISO 10993-3 framework, while for pharmaceuticals it complements reproductive-toxicity assessment concepts described in ICH guideline S5(R2). Comparable in-life and histological sperm endpoints also appear in OECD reproductive toxicity test guidelines.

Testing Samples

Food and Health Products

Novel food ingredients, health foods (functional foods), food additives, processing aids, excipients, and ingredients with new manufacturing processes are common test articles. In jurisdictions applying the GB 15193 series, the sperm abnormality test is part of the standard toxicological documentation package for product registration and filing.

Chemicals and Industrial Products

Industrial chemicals, intermediates, solvents, polymers, and extracts are evaluated to characterize germ-cell genotoxicity hazards for chemical notification and product safety dossiers.

Pesticides and Agrochemicals

Active ingredients and formulations are screened for potential effects on male fertility and germ-cell integrity as part of pesticide registration and re-registration programs.

Pharmaceuticals and Biologics

Drug candidates, impurities, and degradation products may be assessed as an adjunct to formal reproductive-toxicity studies during early safety evaluation.

Medical Devices and Biomaterials

Polar and non-polar extracts prepared according to ISO 10993-12 from device materials, coatings, and elastomers are tested to satisfy genotoxicity and reproductive-hazard considerations under ISO 10993-3.

Cosmetics and Consumer Products

Ingredients and finished formulations intended for repeated consumer exposure are screened for potential germ-cell toxicity in support of safety assessments.

Testing Items

The core endpoints of the oral sperm abnormality study include:

• Per-animal and group-mean sperm abnormality rates, calculated from at least 1,000 morphologically assessable sperm per animal.
• Classification and tabulation of abnormal morphology categories, such as amorphous, banana-shaped, hookless, folded, double-head, and double-tail sperm.
• Dose–response evaluation across at least three dose levels.
• Comparison of treated groups against the concurrent negative (vehicle) control and the historical control database.
• Body weight monitoring, clinical observations, and confirmation of administered dose accuracy throughout the in-life phase.
• Verification of assay sensitivity through a concurrent positive control, typically cyclophosphamide, methyl methanesulfonate, or mitomycin C.

Testing Methods

Test System and Animal Selection

Sexually mature male mice (commonly 6–10 weeks of age and 25–35 g at study start) are the preferred test system because background abnormality rates are well characterized across common strains; male rats may be used where species relevance dictates. Animals are acclimatized for at least 3–5 days before randomization, identified individually, and housed under controlled temperature, humidity, and light conditions with ad libitum access to water and certified diet.

Dose Group Design

A standard design comprises at least three treated groups, a negative (vehicle) control, and a positive control, with typically 5–10 males allocated per group to ensure adequate surviving animals at scheduled necropsy. The high dose is set at the maximum tolerated dose, a dose producing evident toxicity, or the maximum technically administrable dose, guided by prior acute or repeated-dose data such as LD50 or MTD findings. Successive dose levels are separated by appropriate intervals, commonly a factor of two, to characterize the dose–response relationship. Where necessary, a preliminary dose-range finding study is performed to justify dose selection.

Administration Route and Schedule

The test article is administered by oral gavage at a constant dosing volume (for example, 20 mL/kg body weight for mice, adjusted to the most recent body weight). The classical regimen consists of administration once daily for five consecutive days; extended dosing periods (for example, 28–30 days) may be applied when justified by the study director or by specific regulatory requirements. Animals are then maintained without treatment for a post-exposure interval of approximately 30–35 days so that the germ cells present during dosing complete the full spermatogenic cycle and appear as mature epididymal sperm at sampling.

Specimen Collection and Staining

At scheduled euthanasia, the cauda epididymis is excised, weighed where required, and the sperm released into physiological saline or phosphate-buffered saline by mincing. Smears are prepared on cleaned glass slides, air dried, fixed (for example with methanol), and stained with Giemsa or eosin-based stains. At least two slides are prepared per animal, and slides are coded before scoring to eliminate observer bias.

Microscopic Examination and Scoring

Coded slides are examined at 400× to 1000× magnification by trained personnel. A minimum of 1,000 intact sperm per animal is scored and classified into defined abnormality categories. The sperm abnormality rate for each animal is expressed as the percentage of abnormal sperm among all sperm counted, and group means are calculated for statistical comparison.

Statistical Analysis and Result Interpretation

Abnormality rates of treated groups are compared with the negative control using appropriate statistical methods, typically a chi-square test with significance set at p < 0.05. The result is considered positive when the abnormality rate shows a statistically significant increase with a clear dose–response trend, or when a significant increase occurs at one dose level and exceeds the laboratory historical control range with reproducibility. The result is considered negative when no significant increase is observed up to a dose producing evident toxicity or the maximum administrable dose, with the positive control confirming assay validity.

Quality Assurance and Animal Welfare

Studies should be performed in GLP-compliant facilities with animal care programs consistent with the 3R principles (replacement, reduction, refinement) and institutional animal ethics committee approval. Accredited third-party laboratories operating under ISO/IEC 17025 quality systems provide documented traceability of test article characterization, dose formulation analysis, environmental controls, and scorer proficiency, which strengthens the regulatory acceptability of the final report.

Applications

The mouse and rat sperm abnormality oral toxicity test supports a broad range of regulatory and product-development objectives:

• Toxicological dossiers for health foods, novel foods, and food additives evaluated under national food safety assessment procedures.
• Genotoxicity screening batteries that combine the sperm abnormality assay with the bacterial reverse mutation test and the micronucleus test.
• Reproductive and developmental hazard identification for chemicals, pesticides, and consumer products.
• Biological safety evaluation of medical devices within the ISO 10993-3 framework using device extracts.
• Comparative safety assessment of reformulated products, new raw material suppliers, or changed manufacturing processes.
• Weight-of-evidence follow-up investigations when structure–activity analysis or in vitro assays suggest potential germ-cell activity.

FAQ

Why is oral gavage used instead of other administration routes?

Oral administration reflects the primary human exposure route for foods, drugs, and most chemicals, and gavage ensures accurate, quantifiable dosing for each animal. Alternative routes may be justified when they better represent intended exposure, but the oral route remains the default for standard regulatory submissions.

Why must animals be held for several weeks after dosing?

Sperm sampled from the cauda epididymis at necropsy were exposed as earlier germ-cell stages during the dosing period. A post-exposure interval of approximately 30–35 days allows one complete spermatogenic cycle to elapse, ensuring that any induced abnormalities become detectable in mature sperm.

What is considered a normal background abnormality rate?

Negative control abnormality rates in healthy mice are generally low, typically below 2–3%, but exact values vary by strain, age, and laboratory. Each facility must therefore maintain a historical control database, and interpretations always rely on comparison with concurrent controls and laboratory reference ranges.

Can the test be performed in rats as well as mice?

Yes. Mice are the conventional species because their sperm morphology, spermatogenic timeline, and background rates are extensively characterized, but rats are fully acceptable and may be preferred when the rat is the species used in related toxicity studies.

What are the limitations of the assay?

The assay is a screening test, not a definitive measure of heritable mutations. False positives can arise from non-specific systemic stress or severe toxicity at high doses, so results are interpreted alongside other genotoxicity data and, where indicated, confirmed with follow-up studies such as the dominant lethal assay or definitive reproductive toxicity testing.

How long does a complete study take?

A standard five-day dosing design with a 30–35 day post-exposure period typically requires six to eight weeks from animal receipt to draft report, allowing time for acclimatization, specimen preparation, slide scoring, statistical analysis, and quality review.

How should sponsors prepare samples for submission?

Sponsors should provide the test article with identity, purity, composition, solubility, and stability information, along with any existing acute toxicity data to support dose selection. Clear communication of intended regulatory use helps the laboratory select the appropriate protocol variant and reporting format.